Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6078F)

• Drug Name: CT84.66 Drug Info
• Synonyms: T84.66; Anti-CEA IgG1 radioimmunotherapeutic, City of Hope; Anti-carcinoembryonic antigen IgG1 radioimmunotherapeutic, City ofHope

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM6078F

Molecule-Related Drug Atlas

Drug(s) Targeting Carcinoembryonic antigen CEA (CD66e)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR408701	DMXGE3O	Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
Tusamitamab ravtansine	DMMPSA1	Non-small-cell lung cancer	2C25	Phase 3	[4]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[5]
CAP1-6D	DMEYIVW	Pancreatic cancer	2C10	Phase 2	[6]
Pentacea	DMGY5JC	Small-cell lung cancer	2C25.Y	Phase 2	[7]
GI-6207	DM72O6F	Thyroid cancer	2D10	Phase 2	[8]
CeaVac	DM6Z9BV	Colorectal cancer	2B91.Z	Phase 2	[9]
Labetuzumab I-131	DMNO5UE	Colorectal cancer	2B91.Z	Phase 2	[10]
AVX701	DMOPVIQ	Colorectal cancer	2B91.Z	Phase 1/2	[11]
CAR-T cells targeting CEA	DM6VCPX	Colorectal cancer	2B91.Z	Phase 1/2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carcinoembryonic antigen CEA (CD66e)	TTY6DTE	CEAM5_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00645710) Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery. U.S. National Institutes of Health.
• [2] Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.
• [3] ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [4] Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
• [5] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
• [6] Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
• [7] Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
• [8] Clinical pipeline report, company report or official report of GlobeImmune.
• [9] Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
• [10] National Cancer Institute Drug Dictionary (drug id 692828).
• [11] Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
• [12] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.